复发侵袭性脑膜瘤切除联合铯-131永久性颅内近距离放疗的5年II期试验结果
48和60个月局部控制率分别为73%和48%,优于同部位既往治疗的21%和17%(HR 0.145,p<0.001)。手术相关并发症14%,放射性脑损伤14%且均经药物治愈。
要点
- 复发侵袭性脑膜瘤切除联合Cs-131近距离放疗可显著改善局部控制。
- 48和60个月局部控制率分别为73%和48%,优于既往治疗。
- 手术并发症与放射性脑损伤各占14%,后者均可经药物治愈。
核心结论
- 复发侵袭性脑膜瘤行切除联合Cs-131近距离放疗较同部位既往治疗显著改善局部控制,并发症可接受。
研究设计与样本
- 所有患者接受最大安全切除并放置Cs-131片行近距离放疗。
主要发现
- 中位年龄66岁(范围37-82岁),WHO分级1级1例(3%)、2级26例(90%)、3级2例(7%)。
- 中位影像随访34.8个月(范围0.0-70.9个月)。
- R+CTBT后48和60个月局部控制率分别为73%和48%,同部位既往治疗为21%和17%(HR 0.145,p<0.001)。
- 手术相关并发症4例(14%),包括早期术后感染1例(3%)和延迟伤口裂开合并感染3例(10%)。
- 放射性脑损伤4例(14%),均经药物治疗缓解。
关键数值与推荐
- 局部进展定义为手术床1.5 cm内肿瘤复发,经随访影像判定。
临床怎么用
- 对复发侵袭性脑膜瘤,最大安全切除后放置Cs-131片行永久性近距离放疗可作为改善局部控制的治疗选择。
- 需关注手术伤口并发症及放射性脑损伤,后者多数经药物治疗可缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Maximal resection of meningiomas is the gold standard of therapy, yet recurrence following surgery alone is fairly common, particularly with more aggressive tumors. The authors explored the efficacy of treatment of recurrent, aggressive meningiomas with resection plus Cs-131 collagen tile brachytherapy (R+CTBT). METHODS: This was a prospective, nonrandomized, single-center trial that enrolled patients with recurrent aggressive meningiomas between June 2013 and January 2018. All patients underwent maximal safe resection and placement of Cs-131 tiles for CTBT. Local progression, defined as tumor recurrence within 1.5 cm of the operative bed, was determined on follow-up imaging, and hazard ratios were determined to compare the efficacy of R+CTBT with prior treatment at the same site. RESULTS: Twenty-nine recurrent aggressive meningiomas were treated in 27 patients with a median age of 66 (range 37-82) years. The WHO grade at the time of R+CTBT was grade 1 in 1 (3%) case, grade 2 in 26 (90%), and grade 3 in 2 (7%). The median radiographic follow-up was 34.8 (range 0.0-70.9) months. Local control at 48 and 60 months was 73% and 48%, respectively, following R+CTBT compared with 21% and 17% with prior treatment (HR 0.145, p < 0.001). Surgery-related complications occurred in 4 cases (14%), including 1 case (3%) with early postoperative infection and 3 (10%) with delayed wound breakdown and infection. Radiation brain injury occurred in 4 cases (14%), and each resolved with medical therapy. CONCLUSIONS: This study shows that resection combined with Cs-131 CTBT resulted in significantly improved local control with acceptable complications in patients with recurrent aggressive meningiomas when compared with the prior treatment at the same site.
引用
- Lee KE, Catapano JS, Eschbacher JM, et al. Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants for recurrent aggressive meningiomas: 5-year results from a prospective phase 2 trial. J Neurosurg. 2026. PMID: 42030558. doi:10.3171/2025.12.JNS25868
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。